DCLASSY in Daegu: avoiding overcorrection when it cannot be reversed
When you look for the best clinic for DCLASSY in Daegu, the first thing to check is neither price nor equipment. It is one sentence: this class has no dissolving agent. Which makes getting depth and dose right at the start most of the treatment.
The short version
DCLASSY is a calcium hydroxylapatite (CaHA) product, licensed in Korea as a tissue-augmentation material for the temporary improvement of facial wrinkles. Because no dissolving agent is established for this class, avoiding overcorrection becomes the core skill. And DCLASSY’s own trial data is not publicly available — meaning Radiesse’s evidence does not simply transfer to it.
Why “do not overcorrect” is the first sentence for this product
If a hyaluronic acid filler goes in too heavily, hyaluronidase can reduce it. This class has no such route. In cadaveric arterial work, intravascular CaHA was not broken down even with hyaluronidase.
So the design runs the other way. With hyaluronic acid you can place generously and refine; here it is safer to start short and add next time. Too little can be topped up at a later session; too much can only be waited out.
If you are told a single session will finish the job, it is reasonable to ask how that sits with this property.
The principle of not placing it superficially
In pooled CaHA adverse-event data, 89% were nodules and 60% appeared more than a month later. Something palpable soon after treatment is usually a non-inflammatory lump where product has pooled in one plane. In an ultrasound study of 27 patients, these nodules all sat within the fascial layer.
Placed too superficially and concentrated, it can be felt or seen through the skin. CaHA is white, so shallow placement also brings a colour problem. That is why “not too superficial” and “not all in one spot” recur throughout this class.
Same class as Radiesse, but not the same evidence
| Item | Radiesse | DCLASSY |
|---|---|---|
| Korean licence | 2010 — facial wrinkles, hand volume | Tissue-augmentation material — temporary improvement of facial wrinkles |
| Published trials of the product itself | Several, including the FDA approval trials | We could not find published data |
| Microsphere concentration and gel composition | No published comparison of the two products exists | |
This does not mean DCLASSY is a poor product. It holds an MFDS licence as a tissue-augmentation material. It means only that “it is CaHA, so the Radiesse research applies” cannot be said. Sharing a class and sharing an evidence base are different claims.
For context, a 2024 systematic review of 13 controlled CaHA studies covering 1,171 subjects noted risk of bias in study design and heterogeneity large enough that pooled analysis was not feasible. That is the state of the evidence for the class as a whole.
Authentic product and licence numbers — how to check
In Korea DCLASSY is manufactured by CGBio and supplied by DNC Aesthetics. The box carries the product licence number required under the Medical Devices Act.
The long number printed on clinic websites and leaflets is usually an advertising pre-review number, not a product licence number. They are different numbers. You may ask to see the box before treatment — we do that on request.
Summary — what is established and what is not
| Established | Not established |
|---|---|
| Korean licence as a tissue-augmentation material for temporary improvement of facial wrinkles | Published trial data for DCLASSY itself |
| CaHA is not dissolved by hyaluronidase (cadaveric artery) | Any primary study of a reversal agent for this class |
| 89% of adverse events were nodules; 60% after one month | A product-specific nodule rate for DCLASSY |
| Early nodules: all 27 within the fascial layer on ultrasound | Any comparison with Radiesse on microsphere concentration or gel |
| 13 controlled CaHA studies, 1,171 subjects, risk of bias noted | National adverse-event tallies |
Worth asking in consultation
- Whether you were told first that it cannot be reversed — the opening sentence for this class.
- Which plane it goes into — the plan for avoiding superficial pooling.
- How much goes in at one session — starting short, or trying to finish in one go.
- How far DCLASSY’s own data goes — whether it is being explained using Radiesse data.
- The box and its licence number — distinguished from the advertising review number.
- The route if a nodule appears — management differs by timing.
How we judge it at Miso Clinic
Rather than applying DCLASSY uniformly for loss of firmness, we assess suitability by looking at the depth of the hollow, skin thickness, and whether the goal justifies a material that cannot be reversed.
We start short on volume. Leaving room to add at a later session is safer in this class than producing a finished picture in one visit. And we say plainly in consultation that DCLASSY’s own clinical data is not published — not as an argument against the product, but because separating what is known from what is not is the honest thing to do.
Which treatment suits you can differ with skin condition, how much change you want and what you have had before.
Frequently asked questions
Can DCLASSY be dissolved if it goes in badly?
No dissolving agent is established for this class. In cadaveric arterial work, intravascular CaHA was not broken down even with hyaluronidase. That is why avoiding overcorrection is the core skill.
Why place less than needed?
Because too little can be added at a later session, while this class offers no route to reduce what is already in. The design runs opposite to hyaluronic acid.
Is DCLASSY the same as Radiesse?
They share the CaHA class but not the evidence. We could not find published trial data for DCLASSY itself, and no published comparison of the two products on microsphere concentration or gel composition exists. Sharing a class and sharing an evidence base are different claims.
What is it licensed for in Korea?
It is licensed as a tissue-augmentation material for the temporary improvement of facial wrinkles. It is manufactured in Korea by CGBio and supplied by DNC Aesthetics.
What happens if a nodule appears?
Timing tells you what it is. An early palpable lump is usually product pooled in one plane; in an ultrasound study of 27 patients all sat within the fascial layer. Something appearing more than a month later needs a different approach, so telling us when you first felt it matters.
Why must it not be placed superficially?
Concentrated in a shallow plane it can be felt or seen through the skin. CaHA is white, so shallow placement also brings a colour problem.
How do I check the product is genuine?
The box carries the product licence number required under the Medical Devices Act. The long number on clinic leaflets is usually an advertising pre-review number instead. You may ask to see the box before treatment.
How strong is the evidence for this class overall?
A 2024 systematic review of 13 controlled CaHA studies covering 1,171 subjects noted risk of bias in design and heterogeneity large enough that pooled analysis was not feasible.
Further reading
Author and clinic
Dr Lee Chi-Hak, Director, Miso Clinic
4F Bombom Building, 125 Dongdeok-ro, Jung-gu, Daegu (Kyungpook National University Hospital station, exit 1)
+82 53-428-2700 · www.clinicmiso.co.kr
References
- MFDS product licence — tissue-augmentation material, indicated for the temporary improvement of facial wrinkles. Manufactured by CGBio, supplied by DNC Aesthetics
- Yankova M, et al. Aesthetic Surgery Journal 2021;41(5):NP226 (intravascular CaHA not dissolved despite hyaluronidase, cadaveric artery)
- Amiri M, et al. Journal of Clinical Medicine 2024;13(6):1686 (13 controlled CaHA studies, 1,171 subjects — risk of bias and heterogeneity prevented pooled analysis; dorsal hand 7/112 = 6.2%)
- Schelke LW, et al. Dermatologic Surgery 2023;49(6):588 (27 patients, non-inflammatory nodules on 18 MHz ultrasound — all within the fascial layer)
- Convery C, Davies E, Murray G, Walker L. J Clin Aesthet Dermatol. 2021;14(7):E59 (delayed nodules defined as “at least two weeks after injection”)
- Medical Devices Act art. 20 — labelling requirements including the product licence number
- Medical Service Act art. 56(2) — restriction on testimonial advertising
What we could not verify
- Published clinical trial data for DCLASSY itself — we could not find it.
- Any published comparison with Radiesse on microsphere concentration or gel composition.
- A product-specific nodule rate — the 89% and 60% figures are for CaHA as a class.
- Any primary study of a reversal agent for CaHA.
- National adverse-event tallies for CaHA in Korea.
- Any study validating our practice of starting short on volume — it is clinical judgement.
Everything in this column is general information and does not replace medical diagnosis or treatment. Effects and side effects vary with individual skin condition, age and underlying illness, and the same result is not guaranteed for everyone. Any decision to proceed should be made in an in-person consultation with a physician.
← Clinical columns · Reference library · Miso Clinic Daegu
한국어 · English